Case Name: In re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation
Docket No.: 1:14-md-02503
filed:July 22, 2013
court:U.S. District Court, Distrit of Massachusetts
The Solodyn case was filed in the Eastern District of Pennsylvania on July 22, 2013 and later transferred to the District of Massachusetts. Solodyn is a prescription drug for the treatment of acne.
The Solodyn complaint alleges that defendants used an multi-faceted, anticompetitive scheme to thwart generic competition. As alleged in the complaint, this scheme is one in which defendants filed baseless “sham” citizen petitions with the FDA; initiated and maintained “sham” patent suits against multiple potential generic competitors; entered into a so-called “pay for delay” agreements with generic competitors; and “hopped” to different dosage strengths in effort to prevent patients’ from receiving a lower priced generic equivalent at the pharmacy. Due to the defendants’ conduct, consumers and health plains sustained substantial damages in the form of overcharges.